WO2001004121A1 - Verfahren zur herstellung reiner stereoisomeren von tetrahydrofolsäureestersalzen und tetrahydrofolsäure durch fraktionierte kristallisation von tetrahydrofolsäureestersalzen - Google Patents

Verfahren zur herstellung reiner stereoisomeren von tetrahydrofolsäureestersalzen und tetrahydrofolsäure durch fraktionierte kristallisation von tetrahydrofolsäureestersalzen Download PDF

Info

Publication number
WO2001004121A1
WO2001004121A1 PCT/EP2000/006647 EP0006647W WO0104121A1 WO 2001004121 A1 WO2001004121 A1 WO 2001004121A1 EP 0006647 W EP0006647 W EP 0006647W WO 0104121 A1 WO0104121 A1 WO 0104121A1
Authority
WO
WIPO (PCT)
Prior art keywords
tetrahydrofolic acid
acid
tetrahydrofolic
sulfonic acids
diastereomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/006647
Other languages
German (de)
English (en)
French (fr)
Inventor
Hans Rudolf MÜLLER
Rudolf Moser
Viola Groehn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Eprova AG
Original Assignee
Eprova AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eprova AG filed Critical Eprova AG
Priority to DE50015428T priority Critical patent/DE50015428D1/de
Priority to JP2001509730A priority patent/JP4949581B2/ja
Priority to US10/030,693 priority patent/US6858731B1/en
Priority to AU62727/00A priority patent/AU6272700A/en
Priority to EP00949322A priority patent/EP1200436B1/de
Priority to DK00949322T priority patent/DK1200436T3/da
Priority to CA002378869A priority patent/CA2378869C/en
Publication of WO2001004121A1 publication Critical patent/WO2001004121A1/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/02Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2

Definitions

  • the present invention relates to a process for the preparation and enrichment of (6S, ⁇ S) or (6S, ⁇ R) tetrahydrofolic acid ester salts and tetrahydrofolic acid by mixing, in an organic solvent, equimolar or enriched mixtures of diastereomers of addition salts of tetrahydrofolic acid esters with aromatic sulfonic acids produces or dissolves, then crystallizes at least once, and if appropriate hydrolyzes them to (6S, ⁇ S) - or (6S, ⁇ R) -tetrahydrofolic acid and crystallizes them as free acid or isolates them in the form of their salts.
  • the addition salts of the (6R, ⁇ S) or (6R, ⁇ R) tetrahydrofolic acid esters with the corresponding sulfonic acids can be isolated from the mother liquors and the corresponding tetrahydrofolic acids or their salts can be obtained by hydrolysis.
  • the asymmetric ⁇ -C atom in the glutamic acid residue can be in the S configuration ( ⁇ S) or in the R configuration ( ⁇ R).
  • the enantiomers of folic acid are referred to below as ( ⁇ S) -folic acid and ( ⁇ R) -folic acid.
  • the naturally occurring folic acid corresponds to ( ⁇ S) -folic acid.
  • Tetrahydrofolic acid corresponds to formula II
  • the asymmetric ⁇ -C atom in the glutamic acid residue can be in the S configuration ( ⁇ S) or in the R configuration ( ⁇ R) and the asymmetric C atom 6 in the tetrahydropterin residue in the S configuration (6S) or R configuration (6R) may be present.
  • the diastereomers of tetrahydrofolic acid are referred to below as (6S, ⁇ S) -, (6S, ⁇ R) -, (6R, ⁇ S) - and (6R, ⁇ R) - tetrahydrofolic acid. The same applies to the tetrahydrofolic acid esters and their derivatives.
  • (6S, ⁇ S) - 6S, ⁇ R) -, (6R, ⁇ S) - and (6R, ⁇ R) - tetrahydrofolic acid esters.
  • the naturally occurring tetrahydrofolic acid corresponds to (6S, ⁇ S) -tetrahydrofolic acid.
  • folic acid, folic acid ester and folic acid ester salt always includes the two enantiomers ( ⁇ S) and ( ⁇ R) and the term tetrahydrofolic acid, tetrahydrofolic acid ester and tetrahydrofolic acid ester salts all possible diastereomers.
  • Tetrahydrofolic acid has found widespread therapeutic use in the form of 5-formyl or 5-methyl derivatives and their physiologically tolerable salts. It has long been known that the biological activity of the naturally occurring diastereomers of reduced folates, e.g. B. the (6S, ⁇ S) - tetrahydrofolic acid, is by far the strongest. It is therefore expedient to provide therapeutic preparations which contain only the most active form or which is at least highly enriched.
  • Tetrahydrofolic acid is generally produced industrially by heterogeneous hydrogenation of the two imine groups in the pterine skeleton of ( ⁇ S) -folic acid, usually giving an equimolar mixture of (6S, ⁇ S) - and (6R, ⁇ S) -tetrahydrofolic acid.
  • the equimolar mixture can be used for pharmaceutical preparations. But you can also do the desired one beforehand Enrich (6S, ⁇ S) -diastereomers of tetrahydrofolic acid by fractional crystallization or obtain it in pure form, for which various processes are known, see for example EP-0495204.
  • this process cannot convince from an economic point of view insofar as the sulfonic acids used for salt formation can only be separated from aqueous mother liquors at great expense, and therefore large volumes of mother liquors containing sulfonic acid have to be disposed of, which is economically unfavorable.
  • EP-0682 026 describes the preparation of stable crystalline (6S, ⁇ S) and (6R, ⁇ S) tetrahydrofolic acid by crystallization from an aqueous medium at certain pH values.
  • the enrichments in the fractional crystallizations are so low that several steps are necessary for an enrichment of the desired diastereomer to over 99.5%. This is associated with large substance losses and the risk of the formation of chemical degradation products.
  • the enrichment of unnatural isomers is particularly complex according to this process.
  • aromatic sulfonic acid salts (addition salts) of tetrahydrofolic acid esters are outstandingly suitable for the preparation of optically pure diastereomers of tetrahydrofolic acid, since only the addition salts of (6S, ⁇ S) or (6S, ⁇ R) diastereomers crystallize out from organic solvents.
  • the invention relates to a process for the preparation and enrichment of (6S, ⁇ S) - or (6S, ⁇ R) -tetrahydrofolic acid ester salts and -tetrahydrofolic acid, which is characterized in that equimolar or enriched mixtures of diastereomers of addition salts of tetrahydrofolic acid esters with in organic solvents produces or dissolves aromatic sulfonic acids, then crystallizes at least once, and then hydrolyzes the crystals to (6S, ⁇ S) - or (6S, ⁇ R) -tetrahydrofolic acid, crystallizes them as free acid or isolates them in the form of a salt.
  • Crystallization at least once in the context of the invention means fractional crystallization to the desired purity.
  • the number of crystallization steps depends mainly on the content of the desired diastereoisomer (s) in the starting product.
  • the addition salts of the tetrahydrofolic acid esters can correspond to the formula III and comprise the (6S, ⁇ S), (6S, ⁇ R), (6R, ⁇ S) and (6R, ⁇ R) diastereomers,
  • R is T or RH, and one of ⁇ or R 2 , or both Ri and R 2 independently of one another are a monovalent hydrocarbon radical or a heterocarbon radical bonded via a C atom and having heteroatoms selected from the group -O-, -S- and - N- represent, HA stands for an aromatic sulfonic acid, and x denotes an integer from 1 to 6 or a fractional number between 0 to 6.
  • R! and R 2 can be selected independently of one another, but they are preferably identical.
  • R 1 and R 2 preferably represent a hydrocarbon radical.
  • R T and R 2 as the hydrocarbon radical can be aliphatic radicals having 1 to 20, preferably 1 to 12, particularly preferably 1 to 8 and particularly preferably 1 to 4 carbon atoms to cycloaliphatic or cycloaliphatic-aliphatic radicals having 3 to 8 ring carbon atoms and 1 to 6 carbon atoms in the aliphatic radical, to aromatic hydrocarbon radicals having 6 to 14 carbon atoms, particularly preferably 6 to 10 carbon atoms, or to aromatic-aliphatic Leftovers with 7 to
  • the heterohydrocarbon residue can be heteroalkyl with 2 to
  • the hydrocarbon radicals can, for example, be selected from the group consisting of linear and branched C 1 -C 20 -alkyl, C 3 -C 8 - and preferably C -C 7 -cycloalkyl, Cs-C ⁇ -cycloalkyl-d-Ce-alkyl and preferably C -C 7 cycloalkyl -CC 4 alkyl, C 6 -C 10 aryl or C 7 -C 2 aralkyl.
  • the heterocarbon residues can be selected from, for example
  • heteroaryl and C 5 -C ⁇ 2 - and preferably C 5 -C 10 heteroaralkyl, the hetero radicals
  • R 1 and R 2 can be linear or branched alkyl, which preferably contains 1 to 12, more preferably 1 to 8, and particularly preferably 1 to 4 carbon atoms. Examples are methyl, ethyl, and the isomers of propyl, butyl, pentyl, hexyl, heptyl, octyl, decyl, dodecyl, tetradecyl, hexadecyl, octadecyl and eicosyl.
  • the alkyl is preferably linear and the alkyl is preferably methyl, ethyl, n-propyl and n-butyl. Alkyl very particularly preferably represents methyl.
  • R 1 and R 2 preferably contain 4 to 7 and particularly preferably 5 or 6 ring carbon atoms.
  • Examples of cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. Cyclohexyl is particularly preferred.
  • R T and R 2 preferably contain 4 to 7 and particularly preferably 5 or 6 ring carbon atoms as cycloalkyl-alkyl, and preferably 1 to 4 and particularly preferably 1 or 2 carbon atoms in the aliphatic radical.
  • Examples of cycloalkyl-alkyl are
  • R, and R 2 can be, for example, CrC 4 alkyl-X1-C 2 -C 4 -alkyl as heteroalkyl, where X is O or NC-C 4 alkyl. Examples are methoxyethyl and ethoxyethyl.
  • Ri and R 2 may be, for example, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranyl or piperazinyl as heterocycloalkyl.
  • R T and R 2 can be, for example, pyrrolidinylmethyl or ethyl, piperidinylmethyl or -ethyl, morpholinylmethyl or -ethyl, tetrahydropyranylmethyl or -ethyl or piperazinylmethyl or -ethyl as heterocycloalkyl-alkyl.
  • R and R 2 can be, for example, thiophenyl, furanyl, pyranyl, pyrrolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, quinoiinyl, oxazolyl or isooxazolyl as heteroaryl.
  • Ri and R 2 can be, for example, furanylmethyl or ethyl,
  • a preferred group of compounds of formula III are those in which R ⁇ and R 2 are independently dC 4 alkyl, C 5 - or C 6 cycloalkyl, phenyl, CrC 4 alkylphenyl, benzyl or C 1 -C 4 -alkylbenzyl.
  • R and R 2 are preferably identical radicals.
  • R and R 2 very particularly preferably represent CC 4 alkyl, for example methyl or ethyl.
  • x is preferably an integer or fraction from 0.5 to 4, particularly preferably an integer or fraction from 0.5 to 3, and very particularly preferably an integer or fraction from 0.5 to 2.
  • the aromatic sulfonic acids can contain one to three, preferably one or two, and particularly preferably one sulfonic acid group. Sulfonic acids of hydrocarbon aromatics are preferred.
  • the aromatic sulfonic acids can be unsubstituted or with halogen, linear or branched C 1 -C 8 alkyl, preferably dC 4 alkyl, linear or branched C 1 -C 8 alkoxy, preferably CC alkoxy, and linear or branched CrC 8 haloalkyl, preferably -C-C 4 - Halogenalkyl be substituted.
  • substituents are methyl, ethyl, propyl, butyl, methoxy, ethoxy, trifluoromethyl or trichloromethyl, fluorine and chlorine.
  • the aromatic radical preferably contains a substituent. Among the aromatic groups, phenyl and naphthyl are preferred.
  • aromatic sulfonic acids particularly preferably correspond to the formula IV,
  • R 3 is phenyl, methylphenyl, fluorophenyl, chlorophenyl, trichloromethylphenyl and c trifluoromethylphenyl.
  • Particularly preferred compounds of the formula III are those in which R and R 2 are each methyl, x is 1 or 2 or a fractional number between 0.5 and 2, and HA is phenyl, toluyl, fluorine, chlorine or trifluoromethylphenyl - means sulfonic acid.
  • Substituted radicals are preferably p-tolyl, p-fluoro-, 10 p-chloro- or p-trifluoromethylphenyl.
  • Very particularly preferred compounds of the formula III are those in which R 1 and R 2 are each methyl, x is 1 or 2 or a fractional number between 0.5 and 2, and HA is phenyl- or p-toluenesulfonic acid.
  • the addition salts of the tetrahydrofolic acid esters used according to the invention are new and can be prepared, for example, by esterifying tetrahydrofolic acid in the presence of sulfonic acids, or by esterifying tetrahydrofolic acid salts in a polar organic solvent.
  • 10 tetrahydrofolic acid esters can then be converted into addition salts with sulfonic acids.
  • the hydrogenation can be carried out as described above with alcohol-soluble metal complexes of Ir, Rh or Ru and ditertiary diphosphines as hydrogenation catalysts.
  • the hydrogenation is carried out in an alcohol as a solvent and in the presence of a sulfonic acid
  • Mixtures understood that either contain equal amounts of diastereomers with (6S) and (6R) configuration or an excess of a diastereomer with (6S) or (6R) configuration. It is also possible to use mixtures of diastereomers (6S) and (6R) configurations which have either ( ⁇ S) or ( ⁇ R) configurations, or mixtures of diasteromer pairs 25 with (6S) and (6R) configurations and different ones Configuration on the ⁇ -C atom.
  • the mixtures can contain the (6S, ⁇ S) or (6S, ⁇ R) diastereomer in a proportion of at least 5, preferably at least 20, and particularly preferably at least 30 percent and up to about 75 percent or more.
  • Suitable organic solvents are polar organic solvents, preferably at least 1 g addition salt of a teterahydrofolic acid ester per liter Can dissolve solvents at boiling temperature.
  • solvents are halogenated hydrocarbon (methylene chloride, chloroform, tetrachloroethane, chlorobenzene); Ether (diethyl ether, dibutyl ether, tetrahydrofuran, dioxane, ethylene glycol dimethyl or diethyl ether); Carboxylic acid esters and lactones (methyl acetate, ethyl acetate, methyl propionate,
  • Valerolactone N, N-substituted carboxamides and lactams (dimethylformamide, dimethylacetamide, N-methylpyrrolidone); Ketones (acetone, methyl isobutyl ketone, cyclohexanone); Sulfoxides and sulfones (dimethyl sulfoxide, dimethyl sulfone, tetramethylene sulfone); and alcohols (methanol, ethanol, n- or i-propanol, n-, i- or t-butanol, pentanol, hexanol, cyclohexanol, cyclohexanediol, hydroxymethyl- or dihydroxymethylcyclohexane, benzyl alcohol, ethylene glycol, diethylene glycol,
  • the process can be carried out, for example, by mixing equimolar or enriched mixtures of diastereomers from addition salts of tetrahydrofolic acid esters with aromatic sulfonic acids with a solvent and then heating the mixture to dissolve the addition salts of tetrahydrofolic acid esters and aromatic sulfonic acids.
  • the heating can be carried out up to the boiling point of the solvent.
  • the solution is then cooled to at most the fixed point of a solvent, the (6S, ⁇ S) or (6S, ⁇ R) diastereoisomer or both diastereomers either spontaneously or by inoculation with the desired diastereomer or by concentrating the solution crystallize out, and then can be separated in the usual way by filtration. It has proven to be a particular advantage that the reaction solutions of hydrogenating folate esters or hydrogenating addition salts of folate esters and aromatic sulfonic acids can also be used directly to prepare or enrich the addition salts of tetrahydrofolic acid esters with aromatic sulfonic acids.
  • the observed enrichment of the (6S, ⁇ S) or (6S, ⁇ R) diastereomers in the crystals is so high and the crystallizability of these isomers is so excellent that the process according to the invention can even be used to isolate (6S, ⁇ S) - or ( 6S, ⁇ R) -diastereomers from mother liquors, which predominantly contain (6R, ⁇ S) - or (6R, ⁇ R) -diastereomers.
  • the method according to the invention is outstandingly suitable for separation processes on an industrial scale.
  • the addition salts of (6S, ⁇ S) - or (6S, ⁇ R) - tetrahydrofolic acid esters with sulfonic acids obtained after the separation can then be hydrolyzed in a manner known per se, for example with bases such as NaOH or KOH.
  • bases such as NaOH or KOH.
  • the corresponding (6S, ⁇ S) or (6S, ⁇ R) tetrahydrofolic acids are accordingly obtained.
  • These tetrahydrofolic acids can be isolated in stable form as free acids by crystallization, as described for example in EP-A-0682 026.
  • acids for example sulfonic acids
  • the salts of tetrahydrofolic acids can also be crystallized and, if desired, further enriched (EP-0495204).
  • COD stands for cyclooctadiene.
  • Example A1 a Preparation of ( ⁇ S) -folic acid dimethyl ester benzenesulfonate 5,800 g of ( ⁇ S) -folic acid dihydrate (1.68 mmol) are dissolved in a solution at 40 ° C.
  • the substance decomposes above 150 ° C.
  • Example A2 The clear solution from Example A2 is cooled to room temperature and stirred overnight. The separated solid is filtered off, washed with methanol and tert-butyl methyl ether and dried at 30 ° C and 10 mbar. 9.62 g of colorless crystalline tetrahydrofolic acid dimethyl ester benzenesulfonate (15.24 mmol) are obtained with a (6S, ⁇ S) diastereomer fraction of 99.1%.
  • the mother liquor B1c can be used to prepare the (6R, ⁇ S) dimethyl tetrahydrofolic acid benzene sulfonate as described in Example B5.
  • 4 g (6.34 mmol) of the dimethyl tetrahydrofolic acid benzene sulfonate obtained with a proportion of the (6S, ⁇ S) diastereomer of 99.1% are dissolved in 220 ml of boiling methanol. The mixture is allowed to cool to room temperature, left to stand overnight and the solid which has separated off is filtered off with suction. It is washed with methanol and tert-butyl methyl ether and dried at 35 ° C. and 10 mbar.
  • Example A3 The solution obtained according to Example A3 is allowed to cool to room temperature and the solution is inoculated at 60 ° C. with diastereomerically pure (6S, ⁇ S) tetrahydrofluoric acid dimethyl ester benzenesulfonate. After standing overnight, the solid which has separated out is filtered off with suction, washed with methanol and tert-butyl methyl ether and dried at 35 ° C. and 10 mbar. 3.46 g (5.48 mmol) of dimethyl tetrahydrofolic acid benzenesulfonate are obtained with a (6S, ⁇ S) -diastereomer fraction of 99.9%.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PCT/EP2000/006647 1999-07-14 2000-07-12 Verfahren zur herstellung reiner stereoisomeren von tetrahydrofolsäureestersalzen und tetrahydrofolsäure durch fraktionierte kristallisation von tetrahydrofolsäureestersalzen Ceased WO2001004121A1 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE50015428T DE50015428D1 (de) 1999-07-14 2000-07-12 Verfahren zur herstellung reiner stereoisomeren von tetrahydrofolsäureestersalzen und tetrahydrofolsäure durch fraktionierte kristallisation von tetrahydrofolsäureestersalzen
JP2001509730A JP4949581B2 (ja) 1999-07-14 2000-07-12 テトラヒドロ葉酸エステル塩およびテトラヒドロ葉酸の純粋異性体をテトラヒドロ葉酸エステル塩の分別結晶化によって製造する方法
US10/030,693 US6858731B1 (en) 1999-07-14 2000-07-12 Process for the preparation of pure stereoisomers of tetrahydrofolic acid esters salts and tetrahydrofolic acid by fractionated crystallization of tetrahydrofolic acid esters salts
AU62727/00A AU6272700A (en) 1999-07-14 2000-07-12 Method for making pure stereoisomers of tetrahydrofolic acid ester salts and tetrahydrofolic acid by fractionated crystallisation of tetrahydrofolic acid salts
EP00949322A EP1200436B1 (de) 1999-07-14 2000-07-12 Verfahren zur herstellung reiner stereoisomeren von tetrahydrofolsäureestersalzen und tetrahydrofolsäure durch fraktionierte kristallisation von tetrahydrofolsäureestersalzen
DK00949322T DK1200436T3 (da) 1999-07-14 2000-07-12 Fremgangsmåde til fremstilling af rene stereoisomerer af tetrahydrofolsyreestersalte og tetrahydrofolsyre ved fraktioneret krystallisering af tetrahydrofolsyreestersalte
CA002378869A CA2378869C (en) 1999-07-14 2000-07-12 Method for making pure stereoisomers of tetrahydrofolic acid ester salts and tetrahydrofolic acid by fractionated crystallisation of tetrahydrofolic acid salts

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH01300/99A CH695217A5 (de) 1999-07-14 1999-07-14 Verfahren zur Trennung optischer Isomeren von Tetrahydrofolsäureestersalzen und Tetrahydrofolsäure.
CH1300/99 1999-07-14

Publications (1)

Publication Number Publication Date
WO2001004121A1 true WO2001004121A1 (de) 2001-01-18

Family

ID=4207222

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/006647 Ceased WO2001004121A1 (de) 1999-07-14 2000-07-12 Verfahren zur herstellung reiner stereoisomeren von tetrahydrofolsäureestersalzen und tetrahydrofolsäure durch fraktionierte kristallisation von tetrahydrofolsäureestersalzen

Country Status (13)

Country Link
US (1) US6858731B1 (https=)
EP (1) EP1200436B1 (https=)
JP (1) JP4949581B2 (https=)
CN (1) CN1206229C (https=)
AT (1) ATE412654T1 (https=)
AU (1) AU6272700A (https=)
CA (1) CA2378869C (https=)
CH (1) CH695217A5 (https=)
DE (1) DE50015428D1 (https=)
DK (1) DK1200436T3 (https=)
ES (1) ES2316375T3 (https=)
PT (1) PT1200436E (https=)
WO (1) WO2001004121A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062239A1 (en) * 2002-01-25 2003-07-31 Gmt Fine Chemicals Sa (6s)-5,6,7,8-tetrahydrofolic acid production process

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH694251A5 (de) * 1999-07-14 2004-10-15 Eprova Ag Herstellung von Tetrahydropterin und Derivaten.
PT3817812T (pt) 2018-07-06 2023-12-28 Merck Patent Gmbh Sal cristalino de acido 5-metil-(68)-tetra-hidrofólico e éster etílico de l-isoleucina
CN116836166B (zh) * 2023-06-30 2025-10-31 山东师范大学 一种叶酸衍生物及其制备方法和防治铁死亡中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0348641A2 (de) * 1988-06-29 1990-01-03 EPROVA Aktiengesellschaft Verfahren zur Herstellung von Tetrahydrofolaten
EP0495204A1 (de) * 1991-01-16 1992-07-22 EPROVA Aktiengesellschaft Verfahren zur Herstellung von (6S)- und (6R)-Tetrahydrofolsäure
EP0537492A2 (de) * 1991-10-15 1993-04-21 EPROVA Aktiengesellschaft Stabile Salze von 5,10-Methylentetrahydrofolsäure
EP0682026A1 (de) * 1994-05-09 1995-11-15 EPROVA Aktiengesellschaft Stabile kristalline (6S)- und (6R)-Tetrahydrofolsäure

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS497416A (https=) * 1972-05-12 1974-01-23
US5300503A (en) 1991-11-01 1994-04-05 Fmc Corporation Insecticidal 4,6-diamino-1,2-dihydro-1,3,5-triazine derivatives
US5698693A (en) * 1992-11-16 1997-12-16 The United States Of America As Represented By The Department Of Health And Human Services Process of separating the diastereomers of (6R,6S) -5,6,7,8-tetrahydrofolic acid derivatives
CH686672A5 (de) * 1992-12-01 1996-05-31 Cerbios Pharma Sa Verfahren zur Herstellung von (6S)-5,6,7,8-Tetrahydrofolsaeure.
JP3433301B2 (ja) * 1993-11-25 2003-08-04 アサヒビール株式会社 5,6,7,8−テトラヒドロ−d−ネオプテリンの有機酸塩の製造法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0348641A2 (de) * 1988-06-29 1990-01-03 EPROVA Aktiengesellschaft Verfahren zur Herstellung von Tetrahydrofolaten
EP0495204A1 (de) * 1991-01-16 1992-07-22 EPROVA Aktiengesellschaft Verfahren zur Herstellung von (6S)- und (6R)-Tetrahydrofolsäure
EP0537492A2 (de) * 1991-10-15 1993-04-21 EPROVA Aktiengesellschaft Stabile Salze von 5,10-Methylentetrahydrofolsäure
EP0682026A1 (de) * 1994-05-09 1995-11-15 EPROVA Aktiengesellschaft Stabile kristalline (6S)- und (6R)-Tetrahydrofolsäure

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062239A1 (en) * 2002-01-25 2003-07-31 Gmt Fine Chemicals Sa (6s)-5,6,7,8-tetrahydrofolic acid production process
US7193082B2 (en) 2002-01-25 2007-03-20 Gmt Fine Chemicals Sa (6S)-5,6,7,8-tetrahydrofolic acid production process

Also Published As

Publication number Publication date
CN1206229C (zh) 2005-06-15
CN1360586A (zh) 2002-07-24
JP2003504371A (ja) 2003-02-04
CA2378869C (en) 2006-12-12
JP4949581B2 (ja) 2012-06-13
CA2378869A1 (en) 2001-01-18
US6858731B1 (en) 2005-02-22
DK1200436T3 (da) 2009-02-23
ATE412654T1 (de) 2008-11-15
AU6272700A (en) 2001-01-30
EP1200436B1 (de) 2008-10-29
DE50015428D1 (de) 2008-12-11
EP1200436A1 (de) 2002-05-02
PT1200436E (pt) 2009-02-10
ES2316375T3 (es) 2009-04-16
CH695217A5 (de) 2006-01-31

Similar Documents

Publication Publication Date Title
DE3752384T2 (de) Pteridinderivat enthaltende pharmazeutische Zusammensetzung
DE3853711T2 (de) Zwischenverbindungen für die Synthese von 5,6,7,8-Tetrahydro-L-erythro-biopterin und seiner Derivate.
EP0773221B1 (de) Stabile kristalline Tetrahydrofolsäure-Salze
US4649197A (en) Sulfate of 5,6,7,8-tetrahydro-L-erythro-biopterin and process for preparing the same
EP1200437B1 (de) Verfahren zur herstellung von optisch reinen tetrahydropterinen und derivaten, im speziellen optisch reiner tetrahydrofolsäure und ihren derivaten, durch stereospezifische hydrierung
EP1200436B1 (de) Verfahren zur herstellung reiner stereoisomeren von tetrahydrofolsäureestersalzen und tetrahydrofolsäure durch fraktionierte kristallisation von tetrahydrofolsäureestersalzen
EP3271337B1 (de) Verfahren zur herstellung von (4s)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluormethyl)phenyl]-1,2,3,4-tetrahydro pyrimidin-5-carbonitril
DE69121807T2 (de) 3-[(5-Methyl-2-furanyl)methyl]-N-(4-piperidinyl)-3H-imidazo[4,5-b]-pyridin-2-amin-2-hydroxy-1,2,3-propantricarboxylat
EP0570764B1 (de) Asymmetrische Hydrierung
EP1444234A2 (de) Deuterierte pyrazolopyrimidinone sowie diese verbindungen enthaltende arzneimittel
DE69108743T2 (de) Recematspaltung von trans-2-(2-pyrimidinyl)-7-(hydroxymethyl)octahydro-2h-pyrido[1,2-a]-pyrazin.
EP0600460A1 (de) Verfahren zur Herstellung von (6S)-5,6,7,8-Tetrahydrofolsäure
US12595235B2 (en) Process for producing 4,5-dihydro-1H-pyrazoles and intermediates
DE69111640T2 (de) 7-(Diphenylmethyl)oxy-9a-methoxymitosan, seine Herstellung und Verwendung.
AT392068B (de) Optisch aktive oxo-isoindolinylderivate
EP0167045A1 (de) Benzo (c)(1,8)naphthyridine, Verfahren zu ihrer Herstellung und ihre Verwendung sowie diese Verbindungen enthaltende Zubereitungen
DE2240442A1 (de) Verfahren zur herstellung von aminopenicillinen
EP1518850B1 (de) Enantiomerenangereichertes 2-Butanol
DE1935272C3 (de) 3-Amino-4-benzyl-2-methyl-1'phenyl-3-pyrazolin-S-on-Methansulfonylhalogenid- (1 zu 1) -Molekülverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von 4-Benzyl-3-methansulfonamido-2-methyl-1-phenyl-3-pyrazolin-5-on
KR19980078436A (ko) 알파토코페롤 4-아미노벤조산 에스테르화합물 및 이의 제조방법
US5750716A (en) Method of producing platinum (II) complex
DE2449711C3 (de) Verfahren zur Herstellung von Asparagin und N-Acetyl-asparagin
DE4309123C2 (de) Verfahren zur Herstellung von 2,4-Diamino-6-(hydroxymethyl)pteridin-Salzen
CN114401957A (zh) 一种喹唑啉衍生物的制备方法及其结晶
CH539043A (de) Neues Verfahren zur Herstellung des 4-Benzyl-3-methan-sulfonamido-2-methyl-1-phenyl-3-pyrazolin-5-ons

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000949322

Country of ref document: EP

Ref document number: 008102430

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 10030693

Country of ref document: US

Ref document number: 2378869

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2000949322

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642